Join us for an Aerie Pharmaceuticals Key Opinion Leader event featuring subject-matter experts Laura Periman, MD (Periman Eye Institute) and John Sheppard, MD (Virginia Eye Consultants) who will discuss the current dry eye landscape with a focus on unmet needs and emerging advances in treatment options, including Aerie’s investigational TRPM8 agonist, AR-15512.

AR-15512 is currently in registrational Phase 3 trials for the treatment of dry eye disease. Aerie’s leadership team will provide a brief overview of AR-15512 and an update on the Phase 3 clinical development program. A live question and answer session will follow.